Skip to Content
  • Article
  • Open Access

1 January 2002

Standardizing Wound Treatment Procedures for Advanced Technologies

Clinical Director, University of California San Diego Medical Center, Regional Burn Center/Wound Treatment and Research Center, 200 W Arbor Dr 8896, San Diego, CA 92103-8896.

Abstract

New drugs and tissue replacements are currently being approved and integrated into treatment regimens for chronic wounds. This article focuses on a standardized procedure for the use of specific growth factor, a recombinant human platelet-derived growth factor (rhPDGF-BB) manufactured for topical administration. The recommendations made in this article may not reflect product recommendations made by the manufacturer of the drug. Clinicians must be able to support any off-label indication for use of a product.
Chronic wound care requires a thorough evaluation of extrinsic, intrinsic, and wound environment factors that may impair tissue repair. Extrinsic factors include pressure reduction and relief, appropriate compression, selection of special footwear, patient compliance, and social and environmental factors. Intrinsic factors include medications, concomitant medical problems, vascular status, and therapies directly affecting cellular activity, such as those that occur with radiation therapy. The wound environment is addressed by direct intervention, including cleansing, debridement, dressing selection, and prescription of advanced therapies such as growth factors and skin replacements.
General recommendations for approaching and treating chronic wounds are provided by national guidelines.[1,2,3] Standardized procedures for treating various wound etiologies and for using new technologies, including growth factors and tissue replacements, should be developed, reviewed, and approved by the institution providing care.
The goal of a standardized procedure is to provide general guidelines to treatment that are reproducible and provided at optimal cost. The varying backgrounds of clinicians and caregivers should not prevent them from following similar paths to providing care that is consistent for patients with wounds of similar etiologies.
“Standardize” is defined as “to compare with or conform to a standard,” while a “standard” is defined as “something established as a measure or model to which other similar things should conform. . . .[”4] Standardized procedures entail creating a written generalized guideline to which all health-care providers can conform to provide reproducible cost- and outcome-effective treatment. The initial step in standardizing procedures for any treatment center or institution is to conduct a meeting of all key wound care decision makers. National policies and guidelines for the treatment of chronic wounds should be made available to all attendees.
Standardized procedures may vary depending on the type of treatment or the wound etiology. Components common to all standardized procedures are listed in Table 1. Specific types of treatment and product recommendations should be established by the committee, keeping in mind that the goal of treatment is the most appropriate care on the basis of the patient’s needs and the standard of community practice.
Table 1. Common Components of All Standardized Procedures for Wound Treatment
The following recommended standardized protocol for the use of Regranex Gel (Ortho-McNeil Pharmaceutical, Inc, Raritan, New Jersey) on chronic wounds was adapted from the University of California San Diego Medical Center, Regional Burn Center, Wound Treatment and Research Center as well as Wound Consultants, Inc’s (WCI) (Denver, Colorado) wound treatment protocols.

Methods

The following protocols are suggested for the treatment of problematic wounds that have remained unresponsive to appropriate levels of care.
The patient history should be reviewed for trauma; previous surgery, including previous graft or flap procedures; revascularization; cancer; diabetes; noncompliance; emboli; radiation therapy to the affected area; immunosuppressive diseases; and concomitant diseases. The patient must have a chronic wound, which is defined as being present for at least 2 weeks and unresponsive to appropriate care for the wound etiology.
One or more of the following problems impeding wound closure may be or may have been present: inappropriate pressure reduction; inappropriate footwear; suboptimal levels of compression for venous disease; chemotherapy or radiation therapy; incomplete wound debridement; cytotoxic cleansers and agents, such as povidone-iodine, hydrogen peroxide, or Dakin’s solution, or inappropriate wound dressings or treatments; local-tissue hypoxia; chronic, uncontrolled inflammation or dermatitis; or extensive hyperkeratosis.
A complete vascular assessment is recommended. All peripheral, popliteal, and femoral pulses should be checked. A noninvasive or subsequent invasive vascular test may be required if pulses cannot be found with Doppler ultrasonography or if the pulses are weak. The ankle-brachial index and transcutaneous pressure of oxygen or blood flow should be determined.
The skin should be assessed for temperature, general appearance, periwound appearance, degree of cyanosis, degree of dependent rubor (if applicable), presence or absence of hair, appearance of nails, and overall skin status. The wound should be assessed for size, depth, location, wound base appearance, amount and type of drainage, amount of necrotic tissue, and degree of bacterial presence. One or more of these findings may be noted.
The assessment of patients to determine if they are candidates for growth factor includes a differential diagnosis to determine whether the ulcer etiology has been determined and appropriately addressed, and an assessment of the wound status prior to the application of growth factor.
A differential diagnosis should be made for vasculitic, diabetic, and venous conditions, as well as whether the wound is traumatic in origin, postsurgical, drug induced, or pressure induced.
Wound status should be checked for infection or degree of contamination or colonization; blood (oxygen) perfusion to the wound site; appearance of the wound bed (degree or percentage of viable tissue); amount of necrotic tissue present; and exposure of deep structures such as muscle, bone, capsule, tendon, and fascia.
Sharp debridement should always be given primary consideration. Conservative debridement with enzymes, autolysis, or mechanical means may be considered when this is not possible. Excessive or uncontrolled bleeding must be addressed before the drug is applied. The wound should be thoroughly flushed with a noncytotoxic cleanser, such as sterile saline or water, prior to drug application.
The Regranex Gel should be applied in a thin layer, approximately the thickness of a dime, over the wound surface. Highly to moderately exudating wounds may be covered with a slow-absorbing hydrocellular foam that is cut to extend approximately 1 cm beyond the wound edges or with a nonadhering dressing. Dry to low-exudating wounds may be covered with a saline-moistened gauze. Dressings may be changed daily or every other day in low-exudating wounds. Patients who live in a low-humidity environment may require more frequent moist dressing changes on dry or low-exudating wounds. More frequent, daily changes may be required on very high-exudating wounds.
Regranex Gel should be applied daily or at least once every 2 days. For patients with venous disease requiring sustained compression, such as paste bandages or multilayered wraps that are applied weekly, there is no contraindication to a weekly application of growth factors. There are no studies demonstrating the efficacy of weekly growth factor application. CircAid (CircAid Medical Products, Inc, San Diego, California) offers an excellent means of compression that can be removed daily to facilitate the application of growth factor.
Other treatment recommendations include determining which dressings are most easily tolerated and applied by the patient, and who will apply the drug most effectively (patient, family member, or visiting caregiver). The frequency of dressing changes most appropriate for the patient must also be determined.
The following exclusions are recommended: patients who have yet to receive appropriate levels of care; patients currently responding to their prescribed treatment regimen; patients who are candidates for revascularization; patients whose infection has not been appropriately treated; patients with venous disease unable to tolerate compression; repetitive trauma that cannot be eliminated or reduced; patients currently on drugs that interfere with wound closure; and wounds that cannot be adequately debrided.
Patients must be educated on appropriate dressing and drug application. Appropriate compression or footwear also must be considered to protect the area from further trauma. Patients should receive nutritional guidance and information on proper hydration, the need for a daily foot check for patients with diabetes (using mirror for assistance when necessary), and glucose monitoring.
It is extremely important to inform the patient whenever a drug is used for an indication other than that provided by the manufacturer. Chart documentation must include information stating that the patient was fully informed of the drug’s approved indication along with justification for the clinician’s off-label use. Clinicians also should include a statement clarifying why this off-label use is of potential benefit, the reason for that benefit, and what other options are available. Clinicians who recommend off-label use are relying on their clinical judgment and exercising their choice, and they should be responsible and held accountable for their actions.
Patients treated with growth factors should be seen weekly, more often if this is indicated by ulcer etiology or the patient’s medical status. Wounds should be kept from desiccating. Debridement should be performed whenever necrotic tissue, debris, excessive fibrotic tissue, nonviable tissue, or hyperkeratotic tissue is present. Vascular and surgical consultations are recommended when conservative care is not indicated.
The anticipated time to wound closure is indefinite and based on other factors affecting prognosis. These include, but are not limited to, size, location, duration, and depth of wound, and the overall medical status of patient. Clinical studies suggest that a significant decrease in time to closure and improved treatment outcomes may be attained by the appropriate addition of a growth factor to a treatment regimen that includes good care.
The use of Procuren has not been included or discussed in this protocol. Procuren is not an FDA-approved or FDA-regulated manufactured or prescription drug. WCI does not make recommendations on its inclusion in a treatment protocol.
Clinicians are ultimately responsible for treatment decisions that are based on the individual needs of their patients. Standardized procedures are an indication that the clinician attempted to follow the best possible treatment and appropriate standard of care based on community practice, national guidelines, and standardized procedures compiled by a panel of wound care experts. Following a standardized procedure does not guarantee that a patient will never take legal action. It does significantly reduce their chance of winning a case, however, as suggested by Goebel and Goebel,[6] who concluded that the implementation of, and compliance with, practice guidelines for pressure ulcer prevention affect medical malpractice litigation. National guidelines[1,2,3] support the benefits of standardized procedures in assisting with standardized and reproducible care while deterring legal action.

Conclusion

Development and implementation of standardized treatment procedures for the treatment of chronic wounds assist with establishing reproducible cost- and outcome-effective treatment. Regardless of the medical specialty of the health-care provider, standardization of treatment guidelines provides a means of providing quality care and avoiding conflicting orders. Guidelines are most effective when they are based on national guidelines; scientific literature from well designed randomized, controlled, and blinded studies; and evidenced-based published information from scientific forums, congresses, and meetings. Local practices, anecdotal remedies, and treatments that provide no evidence of benefit are not acceptable for establishing appropriate levels of patient care. The development of guidelines for any institution providing ongoing care of the patient with chronic wounds reduces the risk of legal complications and ensures the best possible outcomes.

References

  1. American Diabetes Association. Consensus Development Conference on Diabetic Foot Wound Care. Diabetes Care 1999, 22, 1354. [Google Scholar]
  2. Drug treatment protocols: management of foot ulcers in patients with diabetes. J Am Pharm Assoc (Wash) 2000, 40, 467.
  3. Bergstrom, N; Bennett, MA; Carlson, CE; et al. Clinical Practice Guideline Number 15: Treatment of Pressure Ulcers. AHCPR publication 95-0652. US Dept of Health and Human Services, Agency for Health Care Policy and Research, Rockville, MD, 1994.
  4. Dorland’s Illustrated Medical Dictionary, 28th Ed, WB Saunders, Philadelphia, 1994.
  5. Wound Consultants Inc. WCI Manual, Denver, 1998.
  6. Goebel, RH; Goebel, MR. Clinical practice guidelines for pressure ulcer prevention can prevent malpractice lawsuits in older patients. J Wound Ostomy Continence Nurs. 1999, 26, 175. [Google Scholar]

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.